1. Home
  2. PLSE vs ATRC Comparison

PLSE vs ATRC Comparison

Compare PLSE & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PLSE
  • ATRC
  • Stock Information
  • Founded
  • PLSE 2014
  • ATRC 2000
  • Country
  • PLSE United States
  • ATRC United States
  • Employees
  • PLSE N/A
  • ATRC N/A
  • Industry
  • PLSE Medical/Dental Instruments
  • ATRC Medical/Dental Instruments
  • Sector
  • PLSE Health Care
  • ATRC Health Care
  • Exchange
  • PLSE Nasdaq
  • ATRC Nasdaq
  • Market Cap
  • PLSE 1.2B
  • ATRC 1.1B
  • IPO Year
  • PLSE 2016
  • ATRC 2005
  • Fundamental
  • Price
  • PLSE $19.74
  • ATRC $42.40
  • Analyst Decision
  • PLSE
  • ATRC Strong Buy
  • Analyst Count
  • PLSE 0
  • ATRC 9
  • Target Price
  • PLSE N/A
  • ATRC $43.00
  • AVG Volume (30 Days)
  • PLSE 133.6K
  • ATRC 575.2K
  • Earning Date
  • PLSE 10-30-2024
  • ATRC 02-12-2025
  • Dividend Yield
  • PLSE N/A
  • ATRC N/A
  • EPS Growth
  • PLSE N/A
  • ATRC N/A
  • EPS
  • PLSE N/A
  • ATRC N/A
  • Revenue
  • PLSE N/A
  • ATRC $447,573,000.00
  • Revenue This Year
  • PLSE N/A
  • ATRC $18.02
  • Revenue Next Year
  • PLSE N/A
  • ATRC $12.93
  • P/E Ratio
  • PLSE N/A
  • ATRC N/A
  • Revenue Growth
  • PLSE N/A
  • ATRC 17.56
  • 52 Week Low
  • PLSE $6.60
  • ATRC $18.94
  • 52 Week High
  • PLSE $22.69
  • ATRC $43.11
  • Technical
  • Relative Strength Index (RSI)
  • PLSE 58.11
  • ATRC 78.28
  • Support Level
  • PLSE $17.35
  • ATRC $39.30
  • Resistance Level
  • PLSE $19.90
  • ATRC $41.05
  • Average True Range (ATR)
  • PLSE 1.05
  • ATRC 1.95
  • MACD
  • PLSE 0.15
  • ATRC 0.74
  • Stochastic Oscillator
  • PLSE 80.47
  • ATRC 94.14

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.

About ATRC AtriCure Inc.

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.

Share on Social Networks: